Being a glucose-lowering medication, SGLT2 inhibitors proved to have a significant role in reducing major adverse cardiovascular outcomes and hospitalisation for heart failure initially in patients with diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.